Related Experiment Video
Updated: Aug 21, 2025
10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
1.5K
Let's turn the CAR-T cells ON and OFF precisely.
Jiqin Zhang1, Bing Du1, Mingyao Liu1
1Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Cancer Cell
|November 15, 2022
Summary
Researchers created new on/off switch systems for chimeric antigen receptor (CAR) T-cell therapies. These systems use existing drugs for precise control, enhancing CAR-T cell therapy performance and compatibility.
Area of Science:
- Biotechnology
- Immunotherapy
- Molecular Engineering
Background:
- Chimeric antigen receptor (CAR) T-cell therapy is a promising cancer treatment.
- Current CAR-T cell therapies often lack precise control over their activity.
- Developing controllable CAR systems is crucial for improving safety and efficacy.
Purpose of the Study:
- To engineer novel, tunable ON/OFF switch CAR circuits.
- To utilize clinically approved drugs for CAR system modulation.
- To enhance the controllability, performance, and compatibility of CAR-T cells.
Main Methods:
- Development of CAR circuits incorporating a viral NS3 protease system.
- Integration of clinically approved drugs to act as activators or inhibitors.
- Testing of the developed CAR platforms for controllability and performance in relevant models.
Main Results:
- Successful development of tunable ON/OFF switch CAR circuits.
- Demonstrated superior controllability of CAR-T cell activity using the novel system.
- Exhibited high performance and compatibility of the engineered CAR platforms.
Conclusions:
- The novel CAR circuits offer precise ON/OFF switching capabilities.
- These platforms provide versatile tools for modulating CAR-T cell activity.
- The developed system holds potential for advancing the clinical application of CAR-T cell therapy.
